Top

Published in:

01-12-2010 | Original paper

Urinary phytoestrogens and risk of prostate cancer in Jamaican men

Authors: Maria D. Jackson, Norma D. McFarlane-Anderson, Garfield A. Simon, Franklyn I. Bennett, Susan P. Walker

Published in: Cancer Causes & Control | Issue 12/2010

Abstract

We evaluated the relationship of spot urinary concentrations of phytoestrogens with total prostate cancer and tumor grade in a hospital-based case–control study in Jamaica. Urine samples were analyzed for genistein, daidzein, equol (isoflavones), and enterolactone (lignan) among newly diagnosed cases (n = 175) and controls (n = 194). Urinary concentrations of enterolactone (lignan) were higher among cases. There were no significant differences in median concentrations of isoflavone excretion. Compared with non-producers of equol (reference tertile), men who produced equol were at decreased risk of total prostate cancer (tertile 2: OR, 0.42; CI, 0.23–0.75) (tertile 3: OR, 0.48; CI, 0.26–0.87) (p _trend, 0.020) and high-grade disease (tertile 2: OR, 0.31; CI, 0.15–0.61) (tertile 3: OR, 0.29; CI, 0.13–0.60) (p _trend, 0.001). Higher concentrations of enterolactone were positively related to total prostate cancer (OR, 1.85; CI, 1.01–3.44; p _trend, 0.027) as well as high-grade disease (OR, 2.46; CI, 1.11–5.46; p _trend, 0.023). There were no associations between urinary excretion of genistein and daidzein with risk of prostate cancer. Producers of equol (isoflavone) may be at reduced risk of total- and high-grade prostate cancer whereas enterolactone may increase the likelihood of disease.

Lampe JW (2003) Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr 133(Suppl 3):956S–964SPubMed

Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE (2007) Phyto-oestrogens and risk of prostate cancer in Scottish men. Br J Nutr 98:388–396CrossRefPubMed

Hedelin M, Klint A, Chang ET et al (2006) Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden). Cancer Causes Control 17:169–180CrossRefPubMed

Kurahashi N, Iwasaki M, Inoue M, Sasazuki S, Tsugane S (2008) Plasma isoflavones and subsequent risk of prostate cancer in a nested case–control study: the Japan Public Health Center. J Clin Oncol 26:5923–5929CrossRefPubMed

Nagata Y, Sonoda T, Mori M et al (2007) Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr 137:1974–1979PubMed

Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW (2003) Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 12:665–668PubMed

Ward H, Chapelais G, Kuhnle GG, Luben R, Khaw KT, Bingham S (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the European Prospective into Cancer-Norfolk study. Cancer Epidemiol Biomarkers Prev 17:2891–2894CrossRefPubMed

Tammela T (2004) Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 92:287–295CrossRefPubMed

Gibson TN, Blake G, Hanchard B, Waugh N, McNaughton D (2008) Age-specific incidence of cancer in Kingston and St Andrew, Jamaica, 1998–2002. West Indian Med J 57:81–89PubMed

10.

Anonymous (1997) Cancer incidence in five continents, vol VII. IARC Scientific Publications i-1240

11.

Magee PJ, Rowland IR (2004) Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr 91:513–531CrossRefPubMed

12.

Grace PB, Taylor JI, Low YL et al (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 13:698–708PubMed

13.

Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S (2007) Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 16:538–545CrossRefPubMed

14.

Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64PubMed

15.

Catalona WJ, Partin AW, Slawin KM et al (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279:1542–1547CrossRefPubMed

16.

Etzioni R, Falcon S, Gann PH, Kooperberg CL, Penson DF, Stampfer MJ (2004) Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection? Cancer Epidemiol Biomarkers Prev 13:1640–1645PubMed

17.

Anonymous (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. In: World Health Organisation technical report series 894, i-253

18.

Kilkkinen A, Pietinen P, Klaukka T, Virtamo J, Korhonen P, Adlercreutz H (2002) Use of oral antimicrobials decreases serum enterolactone concentration. Am J Epidemiol 155:472–477CrossRefPubMed

19.

Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H (2001) Determinants of serum enterolactone concentration. Am J Clin Nutr 73:1094–1100PubMed

20.

Valentin-Blasini L, Sadowski MA, Walden D, Caltabiano L, Needham LL, Barr DB (2005) Urinary phytoestrogen concentrations in the U.S. population (1999–2000). J Expo Anal Environ Epidemiol 15:509–523CrossRefPubMed

21.

Park SY, Wilkens LR, Franke AA et al (2009) Urinary phytoestrogen excretion and prostate cancer risk: a nested case–control study in the Multiethnic Cohort. Br J Cancer 101:185–191CrossRefPubMed

22.

Seow A, Shi CY, Franke AA, Hankin JH, Lee HP, Yu MC (1998) Isoflavonoid levels in spot urine are associated with frequency of dietary soy intake in a population-based sample of middle-aged and older Chinese in Singapore. Cancer Epidemiol Biomarkers Prev 7:135–140PubMed

23.

Kurzer MS, Xu X (1997) Dietary phytoestrogens. Annu Rev Nutr 17:353–381CrossRefPubMed

24.

Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577–3584PubMed

25.

Atkinson C, Frankenfeld CL, Lampe JW (2005) Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 230:155–170

26.

Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27–32CrossRefPubMed

27.

Akaza H, Miyanaga N, Takashima N et al (2004) Comparisons of percent equol producers between prostate cancer patients and controls: case–controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol 34:86–89CrossRefPubMed

28.

Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335–339PubMed

29.

Lampe JW, Skor HE, Li S, Wahala K, Howald WN, Chen C (2001) Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 131:740–744PubMed

30.

Vedrine N, Mathey J, Morand C et al (2006) One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women. Eur J Clin Nutr 60:1039–1045CrossRefPubMed

31.

Low YL, Taylor JI, Grace PB et al (2006) Phytoestrogen exposure, polymorphisms in COMT, CYP19, ESR1, and SHBG genes, and their associations with prostate cancer risk. Nutr Cancer 56:31–39CrossRefPubMed

32.

Ward HA, Kuhnle GG, Mulligan AA, Lentjes MA, Luben RN, Khaw KT (2010) Breast, colorectal, and prostate cancer risk in the European Prospective Investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an improved database. Am J Clin Nutr 91:440–448CrossRefPubMed

33.

Travis RC, Spencer EA, Allen NE et al (2009) Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 100:1817–1823CrossRefPubMed

34.

Ozasa K, Nakao M, Watanabe Y et al (2004) Serum phytoestrogens and prostate cancer risk in a nested case–control study among Japanese men. Cancer Sci 95:65–71CrossRefPubMed

35.

Setchell KD, Cassidy A (1999) Dietary isoflavones: biological effects and relevance to human health. J Nutr 129:758S–767SPubMed

36.

Wiseman H (2000) The therapeutic potential of phytoestrogens. Expert Opin Investig Drugs 9:1829–1840CrossRefPubMed

37.

Akaza H, Miyanaga N, Takashima N et al (2002) Is daidzein non-metabolizer a high risk for prostate cancer? A case–controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32:296–300CrossRefPubMed

38.

King RA, Bursill DB (1998) Plasma and urinary kinetics of the isoflavones daidzein and genistein after a single soy meal in humans. Am J Clin Nutr 67:867–872PubMed

39.

Nesbitt PD, Lam Y, Thompson LU (1999) Human metabolism of mammalian lignan precursors in raw and processed flaxseed. Am J Clin Nutr 69:549–555PubMed

40.

Chen LH, Fang J, Sun Z et al (2009) Enterolactone inhibits insulin-like growth factor-1 receptor signaling in human prostatic carcinoma PC-3 cells. J Nutr 139:653–659CrossRefPubMed

41.

Carreau C, Flouriot G, Bennetau-Pelissero C, Potier M (2008) Enterodiol and enterolactone, two major diet-derived polyphenol metabolites have different impact on ERalpha transcriptional activation in human breast cancer cells. J Steroid Biochem Mol Biol 110:176–185CrossRefPubMed

42.

Martin ME, Haourigui M, Pelissero C, Benassayag C, Nunez EA (1996) Interactions between phytoestrogens and human sex steroid binding protein. Life Sci 58:429–436CrossRefPubMed

43.

Lampe JW, Gustafson DR, Hutchins AM et al (1999) Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 8:699–707PubMed

44.

Taylor-Robinson D, Furr PM (1990) Elimination of mycoplasmas from the murine genital tract by hormone treatment. Epidemiol Infect 105:163–168CrossRefPubMed

45.

Low YL, Taylor JI, Grace PB et al (2005) Polymorphisms in the CYP19 gene may affect the positive correlations between serum and urine phytoestrogen metabolites and plasma androgen concentrations in men. J Nutr 135:2680–2686PubMed

46.

Hsing AW, Reichardt JK, Stanczyk FZ (2002) Hormones and prostate cancer: current perspectives and future directions. Prostate 52:213–235CrossRefPubMed

47.

Platz EA, Giovannucci E (2004) The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92:237–253CrossRefPubMed

48.

Johnsen NF, Olsen A, Thomsen BL et al (2010) Plasma enterolactone and risk of colon and rectal cancer in a case–cohort study of Danish men and women. Cancer Causes Control 21:153–162CrossRefPubMed

49.

Kuijsten A, Hollman PC, Boshuizen HC et al (2008) Plasma enterolignan concentrations and colorectal cancer risk in a nested case–control study. Am J Epidemiol 167:734–742CrossRefPubMed

50.

Atkinson C, Skor HE, Fitzgibbons ED et al (2002) Overnight urinary isoflavone excretion in a population of women living in the United States, and its relationship to isoflavone intake. Cancer Epidemiol Biomarkers Prev 11:253–260PubMed

51.

Chen Z, Zheng W, Custer LJ et al (1999) Usual dietary consumption of soy foods and its correlation with the excretion rate of isoflavonoids in overnight urine samples among Chinese women in Shanghai. Nutr Cancer 33:82–87CrossRefPubMed

52.

Wilkinson AP, Wahala K, Williamson G (2002) Identification and quantification of polyphenol phytoestrogens in foods and human biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci 777:93–109CrossRefPubMed

53.

Wu Q, Wang M, Simon JE (2004) Analytical methods to determine phytoestrogenic compounds. J Chromatogr B Analyt Technol Biomed Life Sci 812:325–355PubMed

54.

Statistical Institute of Jamaica (2009) Population census 2001: Jamaica, 2003. Statistical Institute of Jamaica, Kingston

Title: Urinary phytoestrogens and risk of prostate cancer in Jamaican men
Authors: Maria D. Jackson
Norma D. McFarlane-Anderson
Garfield A. Simon
Franklyn I. Bennett
Susan P. Walker
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 12/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-010-9648-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2010

Physical activity, body size and composition, and risk of ovarian cancer

Do students’ perceptions of school smoking policies influence where students smoke?: Canada’s Youth Smoking Survey

Nighttime light level co-distributes with breast cancer incidence worldwide

Comprehensive cancer control: progress and accomplishments

Comprehensive cancer control in the United States: progress and opportunity

Association between body mass index and mortality in patients with glioblastoma mutliforme

Keynote webinar | Spotlight on antibody–drug conjugates in cancer